Skip to content
value.today
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

XLO
$57 Mmarket cap on Oct 29, 2026+182.9% since Jan 2024
Compare
World rank
#20,852
Revenue
$44 M
For year ending December-2025
Net income
$-35 M
-80.1% margin
SEC filing
Employees
76
As of February 28, 2026
SEC filing

Xilio Therapeutics, Inc. in brief

Xilio Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Waltham, Massachusetts, USA. Its market value was $57 M on 29 October 2026, which makes it the 20,852nd largest listed company in the world and the 3,808th largest in the USA on this site. In the year to December 2025 it had sales of $44 M and a net loss of $35 M. It employs about 76 people and Rene Russo is its chief executive. Its shares trade under the symbol XLO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Xilio Therapeutics, Inc.

We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer. Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Our integrated biology and protein engineering approach enables us to design and develop highly potent, masked biologics that are activated, or unmasked, by tumor-specific proteases within the tumor microenvironment. We are currently advancing multiple programs in preclinical and clinical development, including masked multi-specifics, and our clinically-validated masking technology has enabled us to establish top-tier strategic partnerships, including with AbbVie Group Holdings Limited, or AbbVie, and Gilead Sciences, Inc., or Gilead.

From the company's annual report filed with the US SEC: read the report

Xilio Therapeutics, Inc. timeline

2 events, 2021
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 22 October 2021; shares registered for exchange trading on 18 October 2021.

Events of Xilio Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$106 M$212 M$318 M$424 M2023202420252026

World rank over time

▼ down 5,747 places since 2022
2022-01-07: #15147#15,14720222022-12-25: #23881#23,88120222023-07-30: #22933#22,93320232024-01-05: #28987#28,98720242026-03-08: #11270#11,27020262026-08-01: #18945#18,94520262026-10-13: #20483#20,48320262026-10-29: #20894#20,8942026

Rank in USA: #3,176 (Jan 2022) · #4,601 (Dec 2022) · #4,418 (Jul 2023) · #4,363 (Jan 2024) · #2,195 (Mar 2026) · #3,675 (Aug 2026) · #3,730 (Oct 2026) · #3,812 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.0×
Price / book
1.6×
Free cash flow yield
-9.7%
Net margin (TTM)
-20.9%
Operating margin
-95.9%
Return on equity
-32.6%
Liabilities / assets
77.2%
Revenue growth
+590.4%
R&D / revenue
128.0%
Revenue per employee
$576 K
Profit per employee
$-461 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-55M—FY20Fiscal year ending Dec 2021: revenue —, net income $-76M—FY21Fiscal year ending Dec 2022: revenue —, net income $-88M—FY22Fiscal year ending Dec 2023: revenue —, net income $-76M—FY23Fiscal year ending Dec 2024: revenue $6M, net income $-58M$6MFY24Fiscal year ending Dec 2025: revenue $44M, net income $-35M$44MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$44M+590.4%$-42M$-35M-80.1%
Dec 2024$6M—$-61M$-58M-918.6%
Dec 2023——$-79M$-76M—
Dec 2022——$-89M$-88M—
Dec 2021——$-75M$-76M—
Dec 2020——$-55M$-55M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M$1M$-6M$-4.19—
Dec 2024$-18M$0M$-18M$-15.24—
Dec 2023$-69M$0M$-69M$-2.78—
Dec 2022$-76M$2M$-78M$-3.22—
Dec 2021$-81M$1M$-82M$-13.52—
Dec 2020$-36M$2M$-38M$-105.42—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$55M
Net income, trailing 12 months
$-12M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-13M—Dec ’24Three months to Mar 2025: revenue $3M, net income $-13M$3MMar ’25Three months to Jun 2025: revenue $8M, net income $-16M$8MJun ’25Three months to Sep 2025: revenue $19M, net income $-16M$19MSep ’25Three months to Dec 2025 (from the annual report): revenue $14M, net income $10M$14MDec ’25Three months to Mar 2026: revenue $13M, net income $-10M$13MMar ’26Three months to Jun 2026: revenue $19M, net income $-6M$19MJun ’26Three months to Sep 2026: revenue $10M, net income $-6M$10MSep ’26

Latest quarter to Sep 2026: revenue $10M (-47.7% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Xilio Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$44 M
Operating income
$-42 M
Net income
$-35 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$155 M
Total liabilities
$119 M
Total equity
$35 M

As of December-2025

Top 29 institutional investors in Xilio Therapeutics, Inc.#

As of Sep 30, 2026
29 institutions held 3.1 M shares (about 44.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 41.1%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Xilio Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Bain Capital Life Sciences Investors, LLC664,0210 (0.00%)9.40%$6 MNov 16, 2026
2Orbimed Advisors LLC592,3000 (0.00%)8.38%$5 MNov 16, 2026
3Adage Capital Partners GP, L.L.C.464,598+353,057 (+316.53%)6.58%$4 MNov 16, 2026
4Frazier Life Sciences Management, L.P.422,5050 (0.00%)5.98%$4 MNov 16, 2026
5Vanguard Capital Management LLC198,181+19,664 (+11.02%)2.81%$2 MNov 13, 2026
6Stonepine Capital Management, LLC189,092-36,902 (-16.33%)2.68%$2 MNov 13, 2026
7Sio Capital Management, LLC152,4640 (0.00%)2.16%$1 MNov 16, 2026
8Merck & Co., Inc.105,9820 (0.00%)1.50%$1 MNov 13, 2026
9Renaissance Technologies LLC63,553-600 (-0.94%)0.90%$1 MNov 12, 2026
10Morgan Stanley53,674-3,280 (-5.76%)0.76%$0 MNov 13, 2026
11Geode Capital Management, LLC41,449+2,394 (+6.13%)0.59%$0 MNov 6, 2026
12Two Sigma Investments, LP40,104+25,560 (+175.74%)0.57%$0 MNov 16, 2026
13Vanguard Fiduciary Trust Co28,193+5,599 (+24.78%)0.40%$0 MNov 13, 2026
14Bridgeway Capital Management, LLC17,5440 (0.00%)0.25%$0 MNov 16, 2026
15Gsa Capital Partners LLP16,673+3,083 (+22.69%)0.24%$0 MNov 16, 2026
16State Street Corp13,3110 (0.00%)0.19%$0 MNov 12, 2026
17Prudential Financial Inc13,180New0.19%$0 MNov 16, 2026
18HRT Financial LP12,453New0.18%$0 MNov 13, 2026
19Northern Trust Corp11,650New0.16%$0 MNov 16, 2026
20Citadel Advisors LLC11,061-14,889 (-57.38%)0.16%$0 MNov 16, 2026
21BlackRock, Inc.10,908+2,151 (+24.56%)0.15%$0 MNov 13, 2026
22Vanguard Global Advisers, LLC3,359New0.05%$0 MNov 13, 2026
23Steward Partners Investment Advisory, LLC7140 (0.00%)0.01%$0 MNov 13, 2026
24UBS Group AG544+530 (+3785.71%)0.01%$0 MNov 10, 2026
25Royal Bank Of Canada98New0.00%$0 MNov 16, 2026
Show all 29: investors 26 to 29
Institutional investors 26 to 29 in Xilio Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Tower Research Capital LLC (TRC)94New0.00%$0 MNov 16, 2026
27Key Financial Inc590 (0.00%)0.00%$0 MNov 2, 2026
28Jones Financial Companies Lllp58+29 (+100.00%)0.00%$0 MNov 13, 2026
29Citigroup Inc1New0.00%$0 MNov 4, 2026

Mutual funds holding Xilio Therapeutics, Inc.#

12 funds hold shares worth $2 M (about 3.2% of the company). Since their previous reports 11 added shares and 2 sold, buying $1 M net.
Mutual funds holding Xilio Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.142,440$1 M2.0%<0.01%+176%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.35,606$0 M0.50%<0.01%−40%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC19,824$0 M0.28%<0.01%newMay 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors8,219$0 M0.12%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC7,476$0 M0.11%<0.01%newMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC4,514$0 M0.06%<0.01%newMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC2,768$0 M0.04%<0.01%newMay 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP1,507$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP1,116$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC538$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.471$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP254$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Xilio Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$44 K
1 purchase, 1 insider
Sold, 12 months
$6 K
2 sales, 2 insiders
Net, 12 months
$38 K
open market only
Insiders on file
21
since
$1.8 M-$9 K$0Jan 2024: bought $0 (0 trades), sold $4 K (4 trades)Jan 24Feb 2024: bought $0 (0 trades), sold $640 (2 trades)FebApr 2024: bought $369 K (1 trades), sold $0 (0 trades)AprDec 2024: bought $1.8 M (1 trades), sold $0 (0 trades)DecJan 2025: bought $0 (0 trades), sold $9 K (2 trades)Jan 25Jun 2025: bought $73 K (3 trades), sold $0 (0 trades)JunJan 2026: bought $0 (0 trades), sold $6 K (2 trades)Jan 26Mar 2026: bought $44 K (1 trades), sold $0 (0 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Xilio Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed James Samuel ShannonDirectorBuy+5,000$8.790$44 K10,000Form 4
filed Kevin M. BrennanSVP, FINANCE AND ACCOUNTINGSell10b5-1 plan-1,826$0.640$1 K6,371Form 4
filed Christopher James FrankenfieldChief Financial OfficerSell10b5-1 plan-7,030$0.640$4 K24,766Form 4
filed Katarina LuptakovaCHIEF MEDICAL OFFICEROption exercise+16,625——33,250Form 4
filed Kevin M. BrennanSVP, FINANCE AND ACCOUNTINGOption exercise10b5-1 plan+5,000——8,197Form 4
filed Christopher James FrankenfieldChief Financial OfficerOption exercise10b5-1 plan+19,375——31,796Form 4
filed Rene RussoPRESIDENT AND CEO, DirectorOption exercise+44,250——325,422Form 4
filed James Samuel ShannonDirectorBuy+25,000$0.690$17 K70,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Xilio Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
382,761
8.4% of shares · 20.3 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-9.5 reverse split

Trading halts

  • 2026-10-30 15:21 UTC, code LUDP, resumed 15:26 UTC
  • 2026-03-13 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 886 shares at $8.01
  • : 203 shares at $8.43
  • : 581 shares at $8.54
  • : 381 shares at $8.55
  • : 251 shares at $9.02

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Xilio Therapeutics, Inc. scorecard#

Passes 5 of the 15 checks that could be worked out: strongest in growth (2 of 3), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-9.7%Free cash flow is -9.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 3
    • ✓Revenue grew in the newest year590.4%Revenue up 590.4% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.19 vs -15.24Diluted EPS -4.19 in fiscal 2025 against -15.24 the year before (report's currency).
    • ✓Net income higher than five years earlier-$35 M-$35 M in fiscal 2025 against -$55 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$35 MNet income -$35 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-95.9%-95.9% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-132.6%-132.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.58 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-3.43Z-score -3.43 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Xilio Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Xilio Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-95.9%-60.5%
Net margin-80.1%-68.9%
Return on equity-132.6%-61.0%
Revenue growth590.4%15.8%
Free cash flow margin-12.6%-61.5%

4of 7on the Piotroski tests of financial strength

  • Net loss of $35 million, the 6th loss-making year in a row.
  • Free cash flow was negative: -$6 million.

Xilio Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Xilio Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue446.3————
Research and development564152595144
General and administrative302527302411
Operating expenses866779897555
Operating income−42−61−79−89−75−55
Other non-operating income (expense)6.92.32.70.9−0.8−0.7
Income before tax−35−58————
Income tax000000
Net income including minority interests−35−58−76−88−76−55
Net income attributable to shareholders−35−58−76−88−76−55
Earnings per share, basic-4.19-15.24r-2.78-3.22-13.52-105.42
Earnings per share, diluted-4.19-15.24r-2.78-3.22-13.52-105.42
Shares, weighted average (basic)8.43.8r27275.60.5
Balance sheet
Cash and cash equivalents138554512019819
Other current assets2.54.93.44.14.50.0
Current assets145604812420321
Property, plant and equipment3.94.55.97.37.67.4
Right-of-use (leased) assets4.04.65.15.66.06.3
Total assets155716113921836
Accounts payable3.22.61.13.13.15.4
Current liabilities562716211322
Lease liabilities (non-current)5.67.08.19.21011
Total liabilities1195324343342
Retained earnings−419−384−326−249−161−85
Shareholders' equity351837106185−83
Total liabilities and equity155716113921836
Shares outstanding4.53.3r2827270.7
Cash-flow statement
Depreciation and amortization1.51.61.91.81.51.1
Share-based compensation6.96.47.48.45.01.3
Cash from operating activities−5.0−18−69−76−81−36
Capital expenditure−0.5−0.0−0.5−1.9−1.1−2.2
Cash from investing activities−0.5−0.0−0.5−1.9−1.1−2.2
Debt issued————1.0—
Debt repaid—−3.3−6.7—−1.0—
Shares issued————116—
Cash from financing activities8829−6.6−0.126110
Change in cash8211−76−78179−28
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Xilio Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Directors and officers 5 · Material agreement 4 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 9

Xilio Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreement8-K
Directors and officersResults announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Delisting notice8-K
Delisting notice8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Material agreement8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Xilio Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$95 MNo. 2$50 to $250 million17equitySEC
Jan 2021$50 MNo. 1$50 to $250 million16equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Xilio Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2020 for 1 positions, at a median wage of $100 K a year.

Certified, FY2020
1
#1,905 among companies on value.today
Worker positions
1
Median wage offered
$100 K
a year, full-time
Applications filed
2
Xilio Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2020
Job titlePositionsMedian wage offered
Scientist, Protease BiologyBiological Scientists, All Other1$100 K

Where: Waltham, MA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Xilio Therapeutics

Layoffs at Xilio Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2024
Latest
—
2024-03-27
Xilio Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
Xilio Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Xilio Therapeutics, Inc. compares in Biotechnology

  • Market cap$57 M · higher than 28% of 726
  • Revenue$44 M · higher than 58% of 647
  • Net margin-20.9% · higher than 60% of 408
  • Revenue growth590.4% · higher than 95% of 438
  • Price / sales1.0× · lower than 93% of 339
  • Price / book1.6× · lower than 65% of 534
  • FCF yield-9.7% · higher than 57% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Xilio Therapeutics, Inc.🇺🇸$57 M—-20.9%+590.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of February 28, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Xilio Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Xilio Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Xilio Therapeutics, Inc.? Suggest a correction